306 related articles for article (PubMed ID: 26837851)
41. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder.
Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M
Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457
[TBL] [Abstract][Full Text] [Related]
42. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study.
Dannon PN; Iancu I; Grunhaus L
Hum Psychopharmacol; 2002 Oct; 17(7):329-33. PubMed ID: 12415550
[TBL] [Abstract][Full Text] [Related]
43. Combined pharmacotherapy and cognitive behavior therapy in the treatment of panic disorder.
Gelder MG
J Clin Psychopharmacol; 1998 Dec; 18(6 Suppl 2):2S-5S. PubMed ID: 9872706
[TBL] [Abstract][Full Text] [Related]
44. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia.
Bakker A; van Balkom AJ; van Dyck R
Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S25-30. PubMed ID: 11110016
[TBL] [Abstract][Full Text] [Related]
45. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial.
Siegmund A; Golfels F; Finck C; Halisch A; Räth D; Plag J; Ströhle A
J Psychiatr Res; 2011 Aug; 45(8):1042-7. PubMed ID: 21377691
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks.
Buigues J; Vallejo J
J Clin Psychiatry; 1987 Feb; 48(2):55-9. PubMed ID: 3542985
[TBL] [Abstract][Full Text] [Related]
47. Predictors of symptom resolution in panic disorder after one year of pharmacological treatment: a naturalistic study.
Marchesi C; Cantoni A; Fontò S; Giannelli MR; Maggini C
Pharmacopsychiatry; 2006 Mar; 39(2):60-5. PubMed ID: 16555166
[TBL] [Abstract][Full Text] [Related]
48. Effects of the cortisol stress response on the psychotherapy outcome of panic disorder patients.
Wichmann S; Kirschbaum C; Lorenz T; Petrowski K
Psychoneuroendocrinology; 2017 Mar; 77():9-17. PubMed ID: 27987430
[TBL] [Abstract][Full Text] [Related]
49. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone.
Kampman M; Keijsers GP; Hoogduin CA; Hendriks GJ
J Clin Psychiatry; 2002 Sep; 63(9):772-7. PubMed ID: 12363116
[TBL] [Abstract][Full Text] [Related]
50. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia.
Fava GA; Bernardi M; Tomba E; Rafanelli C
Int J Neuropsychopharmacol; 2007 Dec; 10(6):835-8. PubMed ID: 17224089
[TBL] [Abstract][Full Text] [Related]
51. Psychological characteristics of early remitters in patients with panic disorder.
Park HJ; Kim EJ; Ku JI; Woo JM; Lee SH; Chung SK; Lee SY; Kim YR; Kang EH; Lee JH; Kim JH; Yu BH
Psychiatry Res; 2012 May; 197(3):237-41. PubMed ID: 22370156
[TBL] [Abstract][Full Text] [Related]
52. Predictors of outcome of pharmacological and psychological treatment of late-life panic disorder with agoraphobia.
Hendriks GJ; Keijsers GP; Kampman M; Hoogduin CA; Oude Voshaar RC
Int J Geriatr Psychiatry; 2012 Feb; 27(2):146-50. PubMed ID: 21452176
[TBL] [Abstract][Full Text] [Related]
53. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care.
Sharp DM; Power KG; Simpson RJ; Swanson V; Anstee JA
Br J Gen Pract; 1997 Mar; 47(416):150-5. PubMed ID: 9167318
[TBL] [Abstract][Full Text] [Related]
54. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders.
Humble M; Wistedt B
Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 5():21-39. PubMed ID: 1431019
[TBL] [Abstract][Full Text] [Related]
55. A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder.
Hendriks GJ; Keijsers GP; Kampman M; Oude Voshaar RC; Verbraak MJ; Broekman TG; Hoogduin CA
Acta Psychiatr Scand; 2010 Jul; 122(1):11-9. PubMed ID: 19958308
[TBL] [Abstract][Full Text] [Related]
56. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?
Bruce SE; Vasile RG; Goisman RM; Salzman C; Spencer M; Machan JT; Keller MB
Am J Psychiatry; 2003 Aug; 160(8):1432-8. PubMed ID: 12900305
[TBL] [Abstract][Full Text] [Related]
57. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks.
Mavissakalian M; Perel J; Bowler K; Dealy R
Am J Psychiatry; 1987 Jun; 144(6):785-7. PubMed ID: 3296792
[TBL] [Abstract][Full Text] [Related]
58. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults.
Olthuis JV; Watt MC; Bailey K; Hayden JA; Stewart SH
Cochrane Database Syst Rev; 2015 Mar; (3):CD011565. PubMed ID: 25742186
[TBL] [Abstract][Full Text] [Related]
59. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.
Bakker A; van Dyck R; Spinhoven P; van Balkom AJ
J Clin Psychiatry; 1999 Dec; 60(12):831-8. PubMed ID: 10665629
[TBL] [Abstract][Full Text] [Related]
60. Antidepressants versus placebo for panic disorder in adults.
Bighelli I; Castellazzi M; Cipriani A; Girlanda F; Guaiana G; Koesters M; Turrini G; Furukawa TA; Barbui C
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010676. PubMed ID: 29620793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
